Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response aligns with some general boxed-warning themes (CV thrombotic risk; GI bleeding/ulcer risk) but the provided FDA label excerpts do not support most specific interaction/risk-factor statements (e.g., ramipril-specific kidney effects, BP effect reduction, potassium effects, hydration advice, and symptom-triggered counseling). Several clinically oriented recommendations are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Using ibuprofen (an NSAID) carries a risk of serious cardiovascular thrombotic events (e.g., MI and stroke) that can be fatal, and this risk may increase with duration and can occur early in treatment.
BOXED WARNING - Cardiovascular Thrombotic Events; 5.1 - Cardiovascular Thrombotic Events
NSAIDs (including ibuprofen) carry a risk of serious gastrointestinal adverse events (bleeding/ulceration/perforation) that can be fatal, including that such events can occur at any time and without warning symptoms.
BOXED WARNING - Gastrointestinal Risk; 5.2 - Gastrointestinal Bleeding, Ulceration, and Perforation
To minimize potential CV risk, use the lowest effective dose for the shortest duration possible.
5.1 - Cardiovascular Thrombotic Events: “use the lowest effective dose for the shortest duration possible”
Unsupported Statements
Generally, short-term use of ibuprofen with ramipril can be possible.
Not supported by the supplied label excerpts (provided only boxed warnings and selected GI/CV warning sections).
Using ibuprofen with ramipril carries a known risk, especially with frequent use, high doses, older age, dehydration, or kidney disease.
Not supported by the supplied excerpts, which address NSAID CV/GI risks; no ramipril- or kidney-specific interaction language is provided.
Ramipril and ibuprofen can both affect kidney function; combination can increase the risk of acute kidney injury; can reduce how well the blood-pressure medicine works; ACE inhibitors can raise potassium; illness or dehydration can worsen side effects and increase potassium risk; combination can increase potassium levels risk in some patients.
Not supported by the supplied label excerpts.
People are often advised to stay well-hydrated when using an NSAID with ramipril.
Not supported by the supplied label excerpts.
Extra caution or avoidance of ibuprofen with ramipril is more important if the person has chronic kidney disease/reduced kidney function, is 65+ years old, has heart failure, has diabetes, or is dehydrated (vomiting/diarrhea/not drinking enough), or takes other medicines that also affect kidneys (including diuretics and additional blood-pressure medications).
Not supported by the supplied label excerpts (no ramipril/ACE-inhibitor/kidney-injury interaction guidance included).
For many people taking ramipril, acetaminophen is usually preferred for pain or fever.
Not supported by the supplied label excerpts.
Acetaminophen does not carry the same kidney-risk profile as NSAIDs.
Not supported by the supplied label excerpts.
Clinicians may want to know the patient’s kidney status and current medications when assessing ibuprofen use with ramipril.
Not supported by the supplied label excerpts.
Seek prompt medical advice if after taking an NSAID with ramipril the person develops significantly reduced urination, swelling in legs or face, severe weakness/confusion/dizziness, rapid weight gain (fluid retention), or severe/persistent stomach pain/vomiting blood/black stools.
Not supported by the supplied label excerpts. While the excerpts include patient counseling to report symptoms of CV thrombotic events and GI ulceration/bleeding, the specific ramipril-associated symptom list (urination reduction, leg/face swelling, fluid retention) is not present in the provided text.
Contradictions
Important Omissions
The response does not mention the CABG surgery contraindication for ibuprofen (NSAID) despite being part of the boxed-warning/contraindication content included in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Ramipril-specific interaction claims (kidney injury, BP effect reduction, potassium effects, and specific symptom triggers) are largely unsupported by the provided prescribing information excerpts, increasing the risk of overconfidence in guidance not evidenced in the label text supplied.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most ramipril-specific kidney/potassium/BP-effect and hydration/symptom-counseling statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the supplied label-supported content (CV thrombotic boxed warning and mitigation via lowest effective dose/shortest duration; GI boxed warning and associated counseling symptoms). If ramipril-specific interaction details are needed, provide label sections that explicitly address ACE inhibitor/NSAID interactions, potassium effects, and renal outcomes, or remove unsupported specifics.